{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:59:30Z","timestamp":1786715970003,"version":"build-2736575974"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Glucokinase activators (GKAs) enhance glucose phosphorylation by activating glucokinase (GK) expressed in key metabolic organs (such as the liver, pancreas and intestine), thereby initiating cellular glucose metabolism and contributing to improved glycemic control. Among various GKAs under development, dorzagliatin and cadisegliatin (TTP399) are currently the most promising. The gut microbiota plays a critical role in the pathogenesis and progression of metabolic disorders, including obesity and type 2 diabetes. Substantial evidence indicates that long-term administration of oral glucose-lowering agents, such as metformin, can modulate the composition and function of the gut microbiota. Nevertheless, whether GKAs-as emerging oral hypoglycemic agents-also influence gut microbial homeostasis remains unexplored. This study aims to investigate the effects of oral GKAs on intestinal barrier integrity and gut microbiota composition in high-fat diet (HFD)-induced obese\/type 2 diabetic mice. In addition, we compare the differential impacts of distinct GKA agents on glycemic regulation and gut microbial communities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Mice were randomly assigned to receive oral gavage of either a vehicle, dorzagliatin, or TTP399 for four consecutive weeks following 5\u202fweeks of HFD feeding. Throughout the study, changes in key metabolic parameters, intestinal barrier integrity, and inflammatory markers were evaluated. Additionally, fecal samples were collected and subjected to 16S-rRNA gene sequencing for analysis of the gut microbiota composition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Both dorzagliatin and TTP399 exerted beneficial hypoglycemic effects in HFD mice. Furthermore, results also showed that both dorzagliatin and TTP399 regulated the gut microbiota structure in HFD mice, specifically increasing the relative abundance of short-chain fatty acids-producing and anti-inflammatory bacteria. Notably, under the conditions of this study, neither activator exhibited significant effects on intestinal barrier integrity or inflammatory markers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Dorzagliatin and TTP399 are associated with alterations in gut microbiota composition at the genus level in HFD-fed mice, with a concomitant increase in the abundance of beneficial genera, and no significant association with changes in intestinal barrier integrity or inflammation. Further investigation is warranted to elucidate the association between long-term GKAs treatment and microbial communities, as well as the potential relationship between microbial changes and hypoglycemic effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmicb.2026.1783385","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T06:50:09Z","timestamp":1773903009000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of glucokinase activators on the gut microbiota of high-fat diet-induced obese and type 2 diabetic mice"],"prefix":"10.3389","volume":"17","author":[{"given":"Lanyu","family":"Gao","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Laboratory of Diabetes and Metabolism Research, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]},{"name":"Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Laboratory of Diabetes and Metabolism Research, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Zhuo","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Laboratory of Diabetes and Metabolism Research, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yining","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Institute of Metabolic Diseases and Pharmacotherapy, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Laboratory of Diabetes and Metabolism Research, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3390\/microorganisms3020213","article-title":"Does the gut microbiota contribute to obesity? Going beyond the gut feeling","volume":"3","author":"Aguirre","year":"2015","journal-title":"Microorganisms"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/jdi.12673","article-title":"Understanding the role of the gut ecosystem in diabetes mellitus","volume":"9","author":"Aw","year":"2018","journal-title":"J. Diabetes. Investig."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"15718","DOI":"10.1073\/pnas.0407076101","article-title":"The gut microbiota as an environmental factor that regulates fat storage","volume":"101","author":"B\u00e4ckhed","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.2337\/db07-1403","article-title":"Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice","volume":"57","author":"Cani","year":"2008","journal-title":"Diabetes"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1136\/gut.2008.165886","article-title":"Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability","volume":"58","author":"Cani","year":"2009","journal-title":"Gut"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41575-022-00631-9","article-title":"Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms","volume":"19","author":"Cani","year":"2022","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1136\/gutjnl-2016-313099","article-title":"Dietary emulsifiers directly alter human microbiota composition and gene expression ex vivo potentiating intestinal inflammation","volume":"66","author":"Chassaing","year":"2017","journal-title":"Gut"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e450","DOI":"10.1038\/emm.2017.282","article-title":"Akkermansia muciniphila-derived extracellular vesicles influence gut permeability through the regulation of tight junctions","volume":"50","author":"Chelakkot","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1038\/s41467-023-36946-7","article-title":"A phase I open-label clinical trial to study drug-drug interactions of Dorzagliatin and Sitagliptin in patients with type 2 diabetes and obesity","volume":"14","author":"Chen","year":"2023","journal-title":"Nat. Commun."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1124\/mol.111.074401","article-title":"Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs","volume":"80","author":"Eiki","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"9066","DOI":"10.1073\/pnas.1219451110","article-title":"Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity","volume":"110","author":"Everard","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41579-020-0433-9","article-title":"Gut microbiota in human metabolic health and disease","volume":"19","author":"Fan","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nature15766","article-title":"Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota","volume":"528","author":"Forslund","year":"2015","journal-title":"Nature"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/path.5134","article-title":"Increased jejunal permeability in human obesity is revealed by a lipid challenge and is linked to inflammation and type 2 diabetes","volume":"246","author":"Genser","year":"2018","journal-title":"J. Pathol."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.3390\/nu17081303","article-title":"Effects of GLP-1 analogues and agonists on the gut microbiota: a systematic review","volume":"17","author":"Gofron","year":"2025","journal-title":"Nutrients"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1126\/science.1084073","article-title":"Allosteric activators of glucokinase: potential role in diabetes therapy","volume":"301","author":"Grimsby","year":"2003","journal-title":"Science"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"102590","DOI":"10.1016\/j.ebiom.2019.11.051","article-title":"Role of gut microbiota in type 2 diabetes pathophysiology","volume":"51","author":"Gurung","year":"2020","journal-title":"EBioMedicine"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3390\/ijms25010571","article-title":"New-generation Glucokinase activators: potential game-changers in type 2 diabetes treatment","volume":"25","author":"Haddad","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"17737","DOI":"10.3748\/wjg.v20.i47.17737","article-title":"Intestinal microbiota and type 2 diabetes: from mechanism insights to therapeutic perspective","volume":"20","author":"Han","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.1038\/s41467-022-32015-7","article-title":"Oral administration of Blautia wexlerae ameliorates obesity and type 2 diabetes via metabolic remodeling of the gut microbiota","volume":"13","author":"Hosomi","year":"2022","journal-title":"Nat. Commun."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.3390\/microorganisms11081882","article-title":"Effect of Oral Administration of Polyethylene Glycol 400 on gut microbiota composition and diet-induced obesity in mice","volume":"11","author":"Ishibashi","year":"2023","journal-title":"Microorganisms"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"726707","DOI":"10.3389\/fphar.2021.726707","article-title":"Metformin exerts anti-inflammatory and mucus barrier protective effects by enriching Akkermansia muciniphila in mice with ulcerative colitis","volume":"12","author":"Ke","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/s0006-291x(02)00294-2","article-title":"Butyrate reduces colonic paracellular permeability by enhancing PPARgamma activation","volume":"293","author":"Kinoshita","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"960","DOI":"10.2337\/dc20-2684","article-title":"The SimpliciT1 study: a randomized, double-blind, placebo-controlled phase 1b\/2 adaptive study of TTP399, a Hepatoselective Glucokinase activator, for adjunctive treatment of type 1 diabetes","volume":"44","author":"Klein","year":"2021","journal-title":"Diabetes Care"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/4441022a","article-title":"Microbial ecology: human gut microbes associated with obesity","volume":"444","author":"Ley","year":"2006","journal-title":"Nature"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ebiom.2019.03.057","article-title":"Alteration of gut microbiota induced by DPP-4i treatment improves glucose homeostasis","volume":"44","author":"Liao","year":"2019","journal-title":"EBioMedicine"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/1890978","article-title":"The relationship between frequently used glucose-lowering agents and gut microbiota in type 2 diabetes mellitus","volume":"2018","author":"Lv","year":"2018","journal-title":"J. Diabetes Res."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3390\/cells14060463","article-title":"Impact of a high-fat diet on the gut microbiome: a comprehensive study of microbial and metabolite shifts during obesity","volume":"14","author":"Mamun","year":"2025","journal-title":"Cells"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/bf00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/mco.0000000000000209","article-title":"Influence of high-fat diet on gut microbiota: a driving force for chronic disease risk","volume":"18","author":"Murphy","year":"2015","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"E981","DOI":"10.1152\/ajpendo.1997.273.5.E981","article-title":"Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans","volume":"273","author":"Nauck","year":"1997","journal-title":"Am. J. Phys."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e2309255","DOI":"10.1002\/advs.202309255","article-title":"Blautia Coccoides is a newly identified bacterium increased by leucine deprivation and has a novel function in improving metabolic disorders","volume":"11","author":"Niu","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.lfs.2018.11.012","article-title":"Intestinal luminal content from high-fat-fed prediabetic mice changes epithelial barrier function in vitro","volume":"216","author":"Oliveira","year":"2019","journal-title":"Life Sci."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00203-012-0822-1","article-title":"Acetatifactor muris gen. Nov., sp. nov., a novel bacterium isolated from the intestine of an obese mouse","volume":"194","author":"Pfeiffer","year":"2012","journal-title":"Arch. Microbiol."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nm.4236","article-title":"A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice","volume":"23","author":"Plovier","year":"2017","journal-title":"Nat. Med."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"69","DOI":"10.15605\/jafes.037.01.13","article-title":"Review of literature on Akkermansia muciniphila and its possible role in the Etiopathogenesis and therapy of type 2 diabetes mellitus","volume":"37","author":"Sanjiwani","year":"2022","journal-title":"J ASEAN Fed Endocr Soc"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"7021","DOI":"10.1021\/jm3008689","article-title":"Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients","volume":"55","author":"Sarabu","year":"2012","journal-title":"J. Med. Chem."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"112158","DOI":"10.1016\/j.diabres.2025.112158","article-title":"IDF global clinical practice recommendations for managing type 2 diabetes - 2025","volume":"222","author":"Schwarz","year":"2025","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"e25263","DOI":"10.1016\/j.heliyon.2024.e25263","article-title":"Postbiotic potential of Bacillus velezensis KMU01 cell-free supernatant for the alleviation of obesity in mice","volume":"10","author":"Shin","year":"2024","journal-title":"Heliyon"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1136\/gutjnl-2012-303839","article-title":"An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice","volume":"63","author":"Shin","year":"2014","journal-title":"Gut"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1136\/gutjnl-2014-306928","article-title":"Microbiota and diabetes: an evolving relationship","volume":"63","author":"Tilg","year":"2014","journal-title":"Gut"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1038\/nature05414","article-title":"An obesity-associated gut microbiome with increased capacity for energy harvest","volume":"444","author":"Turnbaugh","year":"2006","journal-title":"Nature"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/cei.12293","article-title":"Intestinal microbiota and faecal transplantation as treatment modality for insulin resistance and type 2 diabetes mellitus","volume":"177","author":"Udayappan","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"eaau3441","DOI":"10.1126\/scitranslmed.aau3441","article-title":"Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator","volume":"11","author":"Vella","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1097\/cm9.0000000000000696","article-title":"Gut microbiota and metabolic syndrome","volume":"133","author":"Wang","year":"2020","journal-title":"Chin. Med. J."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"2423040","DOI":"10.1080\/19490976.2024.2423040","article-title":"B. vulgatus ameliorates high-fat diet-induced obesity through modulating intestinal serotonin synthesis and lipid absorption in mice","volume":"16","author":"Wen","year":"2024","journal-title":"Gut Microbes"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/bf01316798","article-title":"Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man","volume":"38","author":"Wettergren","year":"1993","journal-title":"Dig. Dis. Sci."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.cmet.2022.08.003","article-title":"Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota, and T cell-induced inflammation","volume":"34","author":"Wong","year":"2022","journal-title":"Cell Metab."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/nm.4345","article-title":"Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug","volume":"23","author":"Wu","year":"2017","journal-title":"Nat. Med."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.cmet.2020.06.011","article-title":"The gut microbiota in prediabetes and diabetes: a population-based cross-sectional study","volume":"32","author":"Wu","year":"2020","journal-title":"Cell Metab."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s13238-020-00814-7","article-title":"The role of the gut microbiome and its metabolites in metabolic diseases","volume":"12","author":"Wu","year":"2021","journal-title":"Protein Cell"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"154712","DOI":"10.1016\/j.metabol.2021.154712","article-title":"Role of the gut microbiota in type 2 diabetes and related diseases","volume":"117","author":"Yang","year":"2021","journal-title":"Metabolism"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/s41591-022-01803-5","article-title":"Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"28","author":"Yang","year":"2022","journal-title":"Nat. Med."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1161\/circulationaha.118.033714","article-title":"Bacteroides vulgatus and Bacteroides dorei reduce gut microbial lipopolysaccharide production and inhibit atherosclerosis","volume":"138","author":"Yoshida","year":"2018","journal-title":"Circulation"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"156136","DOI":"10.1016\/j.phymed.2024.156136","article-title":"Laoxianghuang polysaccharide promotes the anti-inflammatory cytokine interleukin-10 in colitis via gut microbial linoleic acid","volume":"135","author":"Zhang","year":"2024","journal-title":"Phytomedicine"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"115985","DOI":"10.1016\/j.biopha.2023.115985","article-title":"Ento-a alleviates DSS-induced experimental colitis in mice by remolding intestinal microbiota to regulate SCFAs metabolism and the Th17 signaling pathway","volume":"170","author":"Zhao","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/s41591-022-01802-6","article-title":"Dorzagliatin in drug-na\u00efve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat. Med."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1783385\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T06:50:10Z","timestamp":1773903010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1783385\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":57,"alternative-id":["10.3389\/fmicb.2026.1783385"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2026.1783385","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"article-number":"1783385"}}